Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.)
NCT Number:
NCT04008797
Phase:
I
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Anus, Bladder, Breast, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, Skin, Other Digestive Organ, Other Female Genital, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid
Study Objectives:
To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of
E7386 in combination with other anticancer drug(s). To assess pharmacokinetic (PK) profile of study drug(s)
To assess efficacy (objective response rate [ORR], best overall response [BOR], disease control
rate [DCR], clinical benefit rate [CBR], progression-free survival [PFS], overall survival [OS],
and duration of response [DOR]) of E7386 in combination with other anticancer drug(s)
(Revised per Amendment 06)
Study Documents
(MUSC NetID required for document access)